Acutaas Chemicals growth over the years

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Compounded a year1 yr3 yr
Revenue+33.0%+29.5%
EBITDA+107.1%+57.6%
Net Income+122.3%+62.3%
EPS (adj.)+124.6%+62.3%
Total Assets+28.1%+37.3%
Total Equity+29.6%+42.3%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ACUTAAS₹3,148.30

Acutaas Chemicals Ltd.

· Pharma & Health
₹ CrorePeersANURASAETHERBLUEJETCAPLIPOINTCONCORDBIOEMCUREJBCHEPHARMERISMcap ₹25,776 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
3Y
CAGR
Revenue+33.0+29.5
EBITDA+107.1+57.6
Net Income+122.3+62.3
EPS (adj.)+124.6+62.3
Total Assets+28.1+37.3
Total Equity+29.6+42.3
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.